Skip to main content

GSK plc

corporate_fare Company Profile

GSK plc

GSK·NYSE·Life Sciences·CIK 0001131399

GSK plc researches, develops, and manufactures vaccines, specialty medicines, and general medicines to prevent and treat diseases globally, including in the United Kingdom and the United States. The company operates through two segments: Commercial Operations and Total R&D. Its specialty medicines address conditions such as HIV, respiratory eosinophil-driven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer, encompassing oncology, respiratory/immunology, inflammation, and inhaled medicines. GSK offers a range of vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. General medicines are provided for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. The company also focuses on discovering, developing, and commercializing oral small molecule therapies for oncology and inflammatory diseases. GSK has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases and a strategic alliance with AN2 Therapeutics, Inc. for new TB therapies. Founded in 1715, GSK plc, formerly GlaxoSmithKline plc until May 2022, is headquartered in London, United Kingdom.

GSK plc (NYSE:GSK) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 65 items for GSK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for GSK spans 6-K.

Recent high-impact activity:

  • FDA Grants Accelerated Approval to GSK's Neladalkib for ALK-Positive Lung Cancer
  • GSK Beats Q3 Estimates but Vaccine Slump and £1B Restructuring Charge Drag Shares Down 3.5%
  • GSK Q3: Core EPS +1% CER, Guidance Reaffirmed, New £2.4bn Accelerate Growth Restructuring
  • GSK Beats on Q3 Core EPS, Reaffirms 2026 Guidance as Specialty Drugs Offset Vaccine Slump
  • Ris-Rez Cuts Osteosarcoma Progression Risk 67% in China Phase III

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
£32.67B GBP
Net Income
£6.29B GBP
Diluted EPS
£1.39 GBP
Op. Cash Flow
£7.74B GBP
Free Cash Flow
£6.39B GBP
Gross Profit
£23.65B GBP
Operating Income
£7.93B GBP
Cash & Equivalents
£761M GBP
Total Debt
£14.71B GBP
Debt / Equity
0.92×
Net Margin
19.3%
Shares Outstanding
4.32B sh
Source: 20-F · filed 2026-03-06 · accession 0001131399-26-000004

Short Interest & Short Volume

3.18 days to cover

FINRA reported short interest of 16,148,828 shares in GSK as of the October 30, 2026 settlement, a 10.8% increase from the prior period — about 3.2 days to cover at its recent average daily volume. On November 20, 2026, 44.5% of GSK volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)16,148,828 shares as of October 30, 2026
Change vs prior period▲ 10.8%
Days to cover3.18 at avg daily volume of 5,077,037
Daily short volume (FINRA facilities)44.5% of 950,487 shares on November 20, 2026
5-day average short volume36.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

GSK files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with G →
$47.96 +0.41% today
52-week range · as of 2026-10-28 $42.88 – $61.7
Market cap
$95.85B
Volume
2.7M (0.6× avg)
3-mo avg 4.4M
Live data · 2026-11-21 09:11 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed GSK - Latest Insights

GSK
Nov 17, 2026, 1:26 PM EST
Source: Seeking Alpha
Importance Score:
7
Updated Nov 18, 7:07 AM ET — Nelkarmi's approval covers patients with one prior alectinib or two or more prior ALK TKIs plus platinum chemotherapy, with ORR of 49% and…
Price at Filing: $49.51
Real-time Price: $47.96 info
Change: -$1.55 (-3%) info
Market Cap: $95.854B info
GSK
Oct 28, 2026, 11:45 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $48.75
Real-time Price: $47.96 info
Change: -$0.7949 (-2%) info
Market Cap: $95.854B info
GSK
Oct 28, 2026, 10:45 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $49.08
Real-time Price: $47.96 info
Change: -$1.12 (-2%) info
Market Cap: $95.854B info
GSK
Oct 28, 2026, 3:42 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $51.20
Real-time Price: $47.96 info
Change: -$3.24 (-6%) info
Market Cap: $95.854B info
GSK
Oct 26, 2026, 12:16 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $51.12
Real-time Price: $47.96 info
Change: -$3.16 (-6%) info
Market Cap: $95.854B info
GSK
Oct 26, 2026, 6:51 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $51.04
Real-time Price: $47.96 info
Change: -$3.08 (-6%) info
Market Cap: $95.854B info
GSK
Oct 26, 2026, 6:32 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $50.83
Real-time Price: $47.96 info
Change: -$2.87 (-6%) info
Market Cap: $95.854B info
GSK
Oct 20, 2026, 7:58 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $50.70
Real-time Price: $47.96 info
Change: -$2.74 (-5%) info
Market Cap: $95.854B info
GSK
Oct 19, 2026, 2:08 PM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $49.63
Real-time Price: $47.96 info
Change: -$1.67 (-3%) info
Market Cap: $95.854B info
GSK
Oct 19, 2026, 1:06 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $49.52
Real-time Price: $47.96 info
Change: -$1.56 (-3%) info
Market Cap: $95.854B info
GSK
Sep 15, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $50.03
Real-time Price: $47.96 info
Change: -$2.07 (-4%) info
Market Cap: $95.854B info
GSK
Sep 15, 2026, 2:30 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $50.11
Real-time Price: $47.96 info
Change: -$2.15 (-4%) info
Market Cap: $95.854B info
GSK
Sep 14, 2026, 7:24 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $49.89
Real-time Price: $47.96 info
Change: -$1.93 (-4%) info
Market Cap: $95.854B info
GSK
Sep 14, 2026, 7:04 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $49.83
Real-time Price: $47.96 info
Change: -$1.87 (-4%) info
Market Cap: $95.854B info
GSK
Sep 01, 2026, 7:46 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $50.47
Real-time Price: $47.96 info
Change: -$2.51 (-5%) info
Market Cap: $95.854B info
GSK
Aug 24, 2026, 6:57 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $51.83
Real-time Price: $47.96 info
Change: -$3.87 (-7%) info
Market Cap: $95.854B info
GSK
Aug 24, 2026, 6:20 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $51.85
Real-time Price: $47.96 info
Change: -$3.89 (-8%) info
Market Cap: $95.854B info
GSK
Jul 28, 2026, 1:03 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $54.02
Real-time Price: $47.96 info
Change: -$6.06 (-11%) info
Market Cap: $95.854B info
GSK
Jul 28, 2026, 12:50 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $53.95
Real-time Price: $47.96 info
Change: -$5.99 (-11%) info
Market Cap: $95.854B info
GSK
Jul 22, 2026, 1:58 PM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $50.90
Real-time Price: $47.96 info
Change: -$2.94 (-6%) info
Market Cap: $95.854B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets